Cargando…

The Activity of SN33638, an Inhibitor of AKR1C3, on Testosterone and 17β-Estradiol Production and Function in Castration-Resistant Prostate Cancer and ER-Positive Breast Cancer

AKR1C3 is a novel therapeutic target in castration-resistant prostate cancer (CRPC) and estrogen receptor (ER)-positive breast cancer because of its ability to produce testosterone and 17β-estradiol intratumorally, thus promoting nuclear receptor signaling and tumor progression. A panel of CRPC, ER-...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Yarong Diana, Fu, Melissa, Brooke, Darby G., Heinrich, Daniel M., Denny, William A., Jamieson, Stephen M. F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4061482/
https://www.ncbi.nlm.nih.gov/pubmed/24995161
http://dx.doi.org/10.3389/fonc.2014.00159
_version_ 1782321500752183296
author Yin, Yarong Diana
Fu, Melissa
Brooke, Darby G.
Heinrich, Daniel M.
Denny, William A.
Jamieson, Stephen M. F.
author_facet Yin, Yarong Diana
Fu, Melissa
Brooke, Darby G.
Heinrich, Daniel M.
Denny, William A.
Jamieson, Stephen M. F.
author_sort Yin, Yarong Diana
collection PubMed
description AKR1C3 is a novel therapeutic target in castration-resistant prostate cancer (CRPC) and estrogen receptor (ER)-positive breast cancer because of its ability to produce testosterone and 17β-estradiol intratumorally, thus promoting nuclear receptor signaling and tumor progression. A panel of CRPC, ER-positive breast cancer and high/low AKR1C3-expressing cell lines were treated with SN33638, a selective inhibitor of AKR1C3, in the presence of hormone or prostaglandin (PG) precursors, prior to evaluation of cell proliferation and levels of 11β-PG F(2α) (11β-PGF(2α)), testosterone, 17β-estradiol, and prostate-specific antigen (PSA). A meta-analysis of AKR1C3 mRNA expression in patient samples was also conducted, which revealed that AKR1C3 mRNA was upregulated in CRPC, but downregulated in ER-positive breast cancer. 11β-PGF(2α) and testosterone levels in the cell line panel correlated with AKR1C3 protein expression. SN33638 prevented 11β-PGF(2α) formation in cell lines that expressed AKR1C3, but partially inhibited testosterone formation and subsequently cell proliferation and/or PSA expression only in high (LAPC4 AKR1C3-overexpressing cells) or moderate (22RV1) AKR1C3-expressing cell lines. SN33638 had little effect on 17β-estradiol production or estrone-stimulated cell proliferation in ER-positive breast cancer cell lines. Although SN33638 could prevent 11β-PGF(2α) formation, its ability to prevent testosterone and 17β-estradiol production and their roles in CRPC and ER-positive breast cancer progression was limited due to AKR1C3-independent steroid hormone production, except in LAPC4 AKR1C3 cells where the majority of testosterone was AKR1C3-dependent. These results suggest that inhibition of AKR1C3 is unlikely to produce therapeutic benefit in CRPC and ER-positive breast cancer patients, except possibly in the small subpopulation of CRPC patients with tumors that have upregulated AKR1C3 expression and are dependent on AKR1C3 to produce the testosterone required for their growth.
format Online
Article
Text
id pubmed-4061482
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-40614822014-07-03 The Activity of SN33638, an Inhibitor of AKR1C3, on Testosterone and 17β-Estradiol Production and Function in Castration-Resistant Prostate Cancer and ER-Positive Breast Cancer Yin, Yarong Diana Fu, Melissa Brooke, Darby G. Heinrich, Daniel M. Denny, William A. Jamieson, Stephen M. F. Front Oncol Oncology AKR1C3 is a novel therapeutic target in castration-resistant prostate cancer (CRPC) and estrogen receptor (ER)-positive breast cancer because of its ability to produce testosterone and 17β-estradiol intratumorally, thus promoting nuclear receptor signaling and tumor progression. A panel of CRPC, ER-positive breast cancer and high/low AKR1C3-expressing cell lines were treated with SN33638, a selective inhibitor of AKR1C3, in the presence of hormone or prostaglandin (PG) precursors, prior to evaluation of cell proliferation and levels of 11β-PG F(2α) (11β-PGF(2α)), testosterone, 17β-estradiol, and prostate-specific antigen (PSA). A meta-analysis of AKR1C3 mRNA expression in patient samples was also conducted, which revealed that AKR1C3 mRNA was upregulated in CRPC, but downregulated in ER-positive breast cancer. 11β-PGF(2α) and testosterone levels in the cell line panel correlated with AKR1C3 protein expression. SN33638 prevented 11β-PGF(2α) formation in cell lines that expressed AKR1C3, but partially inhibited testosterone formation and subsequently cell proliferation and/or PSA expression only in high (LAPC4 AKR1C3-overexpressing cells) or moderate (22RV1) AKR1C3-expressing cell lines. SN33638 had little effect on 17β-estradiol production or estrone-stimulated cell proliferation in ER-positive breast cancer cell lines. Although SN33638 could prevent 11β-PGF(2α) formation, its ability to prevent testosterone and 17β-estradiol production and their roles in CRPC and ER-positive breast cancer progression was limited due to AKR1C3-independent steroid hormone production, except in LAPC4 AKR1C3 cells where the majority of testosterone was AKR1C3-dependent. These results suggest that inhibition of AKR1C3 is unlikely to produce therapeutic benefit in CRPC and ER-positive breast cancer patients, except possibly in the small subpopulation of CRPC patients with tumors that have upregulated AKR1C3 expression and are dependent on AKR1C3 to produce the testosterone required for their growth. Frontiers Media S.A. 2014-06-18 /pmc/articles/PMC4061482/ /pubmed/24995161 http://dx.doi.org/10.3389/fonc.2014.00159 Text en Copyright © 2014 Yin, Fu, Brooke, Heinrich, Denny and Jamieson. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Yin, Yarong Diana
Fu, Melissa
Brooke, Darby G.
Heinrich, Daniel M.
Denny, William A.
Jamieson, Stephen M. F.
The Activity of SN33638, an Inhibitor of AKR1C3, on Testosterone and 17β-Estradiol Production and Function in Castration-Resistant Prostate Cancer and ER-Positive Breast Cancer
title The Activity of SN33638, an Inhibitor of AKR1C3, on Testosterone and 17β-Estradiol Production and Function in Castration-Resistant Prostate Cancer and ER-Positive Breast Cancer
title_full The Activity of SN33638, an Inhibitor of AKR1C3, on Testosterone and 17β-Estradiol Production and Function in Castration-Resistant Prostate Cancer and ER-Positive Breast Cancer
title_fullStr The Activity of SN33638, an Inhibitor of AKR1C3, on Testosterone and 17β-Estradiol Production and Function in Castration-Resistant Prostate Cancer and ER-Positive Breast Cancer
title_full_unstemmed The Activity of SN33638, an Inhibitor of AKR1C3, on Testosterone and 17β-Estradiol Production and Function in Castration-Resistant Prostate Cancer and ER-Positive Breast Cancer
title_short The Activity of SN33638, an Inhibitor of AKR1C3, on Testosterone and 17β-Estradiol Production and Function in Castration-Resistant Prostate Cancer and ER-Positive Breast Cancer
title_sort activity of sn33638, an inhibitor of akr1c3, on testosterone and 17β-estradiol production and function in castration-resistant prostate cancer and er-positive breast cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4061482/
https://www.ncbi.nlm.nih.gov/pubmed/24995161
http://dx.doi.org/10.3389/fonc.2014.00159
work_keys_str_mv AT yinyarongdiana theactivityofsn33638aninhibitorofakr1c3ontestosteroneand17bestradiolproductionandfunctionincastrationresistantprostatecanceranderpositivebreastcancer
AT fumelissa theactivityofsn33638aninhibitorofakr1c3ontestosteroneand17bestradiolproductionandfunctionincastrationresistantprostatecanceranderpositivebreastcancer
AT brookedarbyg theactivityofsn33638aninhibitorofakr1c3ontestosteroneand17bestradiolproductionandfunctionincastrationresistantprostatecanceranderpositivebreastcancer
AT heinrichdanielm theactivityofsn33638aninhibitorofakr1c3ontestosteroneand17bestradiolproductionandfunctionincastrationresistantprostatecanceranderpositivebreastcancer
AT dennywilliama theactivityofsn33638aninhibitorofakr1c3ontestosteroneand17bestradiolproductionandfunctionincastrationresistantprostatecanceranderpositivebreastcancer
AT jamiesonstephenmf theactivityofsn33638aninhibitorofakr1c3ontestosteroneand17bestradiolproductionandfunctionincastrationresistantprostatecanceranderpositivebreastcancer
AT yinyarongdiana activityofsn33638aninhibitorofakr1c3ontestosteroneand17bestradiolproductionandfunctionincastrationresistantprostatecanceranderpositivebreastcancer
AT fumelissa activityofsn33638aninhibitorofakr1c3ontestosteroneand17bestradiolproductionandfunctionincastrationresistantprostatecanceranderpositivebreastcancer
AT brookedarbyg activityofsn33638aninhibitorofakr1c3ontestosteroneand17bestradiolproductionandfunctionincastrationresistantprostatecanceranderpositivebreastcancer
AT heinrichdanielm activityofsn33638aninhibitorofakr1c3ontestosteroneand17bestradiolproductionandfunctionincastrationresistantprostatecanceranderpositivebreastcancer
AT dennywilliama activityofsn33638aninhibitorofakr1c3ontestosteroneand17bestradiolproductionandfunctionincastrationresistantprostatecanceranderpositivebreastcancer
AT jamiesonstephenmf activityofsn33638aninhibitorofakr1c3ontestosteroneand17bestradiolproductionandfunctionincastrationresistantprostatecanceranderpositivebreastcancer